Entrada Therapeutics
Aims to treat devastating diseases through the intracellular delivery of biologics.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 -11.7x EV/EBITDA | round | |
| investor | €0.0 | round | |
* | N/A | $100m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | - | 63 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | - | - | 24 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | (5 %) | 31 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | - | - | 77 % | 59 % |
Source: Company filings or news article
Related Content
Entrada Therapeutics is a clinical-stage biopharmaceutical company that is focused on developing a new class of medicines to treat a variety of devastating diseases. The company's proprietary Endosomal Escape Vehicle (EEV)™ platform is designed to enable the intracellular delivery of a wide range of therapeutics into a variety of organs and tissues.
The company's EEV platform is based on a novel mechanism that allows for the efficient escape of therapeutics from endosomes, which are membrane-bound vesicles that can trap and degrade drugs before they can reach their intracellular targets. This allows Entrada's EEV-therapeutics to reach and engage previously undruggable intracellular targets, which could lead to the development of new treatments for a wide range of diseases.
Entrada is currently developing a pipeline of EEV-therapeutics for the treatment of a variety of diseases, including Duchenne muscular dystrophy and other neuromuscular diseases. The company has received authorization from regulatory authorities in the United Kingdom and the European Union to initiate clinical trials of its lead product candidate, ENTR-601-45, for the treatment of Duchenne muscular dystrophy.
Keywords: Biopharmaceutical, Intracellular Therapeutics, EEV Platform, Oligonucleotide Therapies, Drug Delivery, Clinical-Stage, Nasdaq:TRDA, Endosomal Escape Vehicle, Rare Diseases, Gene Therapy.